Davis Capital Management
AMRX icon

Davis Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Davis Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$383 Buy
19
+9
+90% +$162 ﹤0.01% 688
2026
Q2 		$173 Buy
+10
New +$137 ﹤0.01% 890

Other funds holding AMRX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Tucker Asset Management
Tucker Asset Management Littleton, Colorado $406M AUM 20.49% 1-Year Est. Return
Exchange Traded Concepts
Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return
Signature Wealth Management Partners
Signature Wealth Management Partners Montvale, New Jersey $234M AUM 23.06% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Diversify Advisory Services
Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return
Diversify Wealth Management
Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Davis Capital Management's AMRX Position: Q3 2026 in Review

Davis Capital Management increased its Amneal Pharmaceuticals (AMRX) stake by 90% in Q3 2026, buying an estimated $162 and bringing the position to 19 shares worth $383. The position accounts for ﹤0.01% of the portfolio, ranked #688.

Davis Capital Management first reported a position in AMRX in Q2 2026 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Davis Capital Management held 19 shares of Amneal Pharmaceuticals worth $383 as of Q3 2026.
  • Davis Capital Management bought 9 Amneal Pharmaceuticals shares in Q3 2026, an estimated $162.
  • Amneal Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #688 holding.
  • Davis Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.